

Bangkok Dusit Medical

Bangkok Dusit Medical Services
Public Company Limited

BDMS

Bloomberg BDMS.TB
Reuters BDMS.BK



Healthier operations and earnings

We maintain our positive view on BDMS with a 3-month tactical call of Outperform (end-2023 TP of Bt34/share). Earnings in 4Q22 will grow on rising non-COVID-19 services for Thai but especially international patients with a jump in appointments after Thailand's reopening. Over 2023-25, BDMS targets revenue growth at 10-12% p.a. driven by more specialized services, enhancing its patient base and increasing capacity.

BDMS revises up its 2022 revenue target. BDMS has raised its 2022 revenue growth target to 22% (from 15-20% earlier and vs 30% YoY growth in 9M22) after seeing strong momentum continuing through October with YoY double-digit growth. Backing the surge in revenue is growing non-COVID-19 services for Thai and especially international patients: BDMS has seen a jump in appointments in 4Q22 from patients from CLMV, the Middle East and Europe. It targets revenue from international patient services to reach pre-COVID-19 level in 4Q22 (from 94% in 3Q22) with an increase in revenue contribution from international patient services to 30% of revenue in 4Q22 from 24% in 3Q22.

Revenue uptrend in 2023-25. Excluding the COVID-19 services in 2022, BDMS targets revenue growth at 10-12% p.a. in 2023-25. For the Thai patient market, its strategies include offering more specialized services through its Centers of Excellence (50% of revenue), increasing services under the social security scheme (SC, 3% of revenue) and enhancing its ecosystem through digital health services to enlarge its patient base. For the international market, BDMS sees growth potential in new markets such as Saudi Arabia and Bangladesh, in long-stay tourists and in wellness services. It targets EBITDA margin at 23-24%, relatively stable from 2021. It plans to add ~500 beds or 6% to reach ~9,000 beds in 2026, with a focus on Thailand's eastern region, where the economy and business activities are being sparked by the development of EEC.

Earnings forecast maintained. We forecast core earnings at Bt12.2bn in 2022 (58% growth), suggesting 4Q22's earnings will grow YoY but drop QoQ on seasonality and lower revenue from COVID-19 services, and Bt13.7bn in 2023 (12% growth). Our 2023-25 revenue growth assumption lines up with its long-term target but we assume EBITDA margin of 25-26%, reflecting our positive view on room to improve margin through better asset utilization upon a larger patient base and growing revenue from Centers of Excellence.

Risks. Unpredictable events such as another pandemic that will interrupt patient traffic, intense competition, workforce shortage and regulatory risk.

Forecasts and valuation

Year to 31 Dec	Unit	2020	2021	2022F	2023F	2024F
Revenue	(Btmn)	65,166	71,541	87,165	92,867	99,508
EBITDA	(Btmn)	14,982	17,622	22,782	25,072	26,988
Core profit	(Btmn)	6,037	7,736	12,220	13,733	15,066
Reported profit	(Btmn)	7,214	7,936	12,220	13,733	15,066
Core EPS	(Bt)	0.38	0.49	0.77	0.86	0.95
DPS	(Bt)	0.55	0.45	0.50	0.50	0.50
P/E, core	(x)	75.6	59.6	37.7	33.6	30.6
EPS growth, core	(%)	(36.9)	26.9	58.0	12.4	9.7
P/BV, core	(x)	5.2	5.5	5.2	4.9	4.6
ROE	(%)	6.8	8.6	13.6	14.4	14.8
Dividend yield	(%)	1.9	1.6	1.7	1.7	1.7
FCF yield	(x)	5.3	0.0	2.3	3.3	3.5
EV/EBIT	(x)	41.5	41.3	28.1	24.7	22.2
EBIT growth, core	(%)	(44.4)	2.8	45.5	12.1	9.2
EV/CE	(x)	4.3	4.4	4.4	4.3	4.3
ROCE	(%)	3.0	5.3	8.7	10.1	11.3
EV/EBITDA	(x)	30.4	26.5	20.3	18.1	16.5
EBITDA growth	(%)	(16.9)	17.6	29.3	10.1	7.6

Source: InnovestX Research

Tactical: OUTPERFORM (3-month)

Stock data

Last close (Nov 28) (Bt)	29.00
Target price (Bt)	34.00
Mkt cap (Btbn)	460.87
Mkt cap (US\$mn)	12,963

Beta	L
Mkt cap (%) SET	2.33
Sector % SET	5.35
Shares issued (mn)	15,892
Par value (Bt)	0.10
12-m high / low (Bt)	32 / 21.5
Avg. daily 6m (US\$mn)	37.17
Foreign limit / actual (%)	25 / 22
Free float (%)	68.3
Dividend policy (%)	≥ 50

2022 Sustainability / 2021 ESG Score

Sustainability Index (THSI)	Included
-----------------------------	----------

ESG Bloomberg Score	57.69
Environmental Score	52.31
Social Score	37.06
Governance Score	83.59

Source: Bloomberg Finance LP

Share performance

(%)	1M	3M	12M
Absolute	(2.5)	4.5	27.8
Relative to SET	(3.2)	5.1	25.6

Source: SET, InnovestX Research

Analyst

Raweenuch Piyakriengkai

Fundamental Investment

Analyst on Securities

(66-2) 949-1002

raweenuch.piyakriengkai@scb.co.th

Value proposition

BDMS is Thailand's largest private hospital operator (53 hospitals with over 8,500 beds) and is one of the top five private hospital operators in the world by market capitalization. BDMS is placing itself to get in on rising demand for quality healthcare and to provide the entire spectrum of healthcare service, from preventive (wellness business) to curative and rehabilitative.

Business outlook

We forecast continued improvement in earnings with 58% growth in 2022 to Bt12.2bn, above pre-COVID-19 level, and 12% growth in 2023 to Bt13.7bn with more Thai patients coming for care after COVID-19 eased and improving international patient services that will offset the fading COVID-19 services. Excluding the COVID-19 services in 2022, BDMS targets revenue growth at 10-12% p.a. in 2023-25. BDMS is strengthening its Thai patient base, mainly middle incomers, by collaborating with insurance companies to provide exclusive health insurance policies. Besides the bed expansion, BDMS has actively expanded into non-hospital businesses including digital health services, setting up the Genomic Center, and investing in *BDMS Silver Wellness & Residence*, a mixed-use project (clinic, hotel and residential) for the wellness business. Although the non-hospital businesses are still small at 4-5% of revenue, BDMS sees growth opportunities from broadening its scope of services and expects revenue from non-hospital businesses to reach 20% of revenue in the future.

Bullish views	Bearish views
1. Sound fundamentals, providing the entire spectrum of healthcare, from preventive (wellness business) to curative and rehabilitative.	1. Concern about competition.
2. Collaboration with Ping An Health Insurance Company of China, Ltd. (Ping An Health) which is a part of Ping An Insurance Group Company of China, Ltd., the largest insurance company in China.	
3. Laggard play	

Key catalysts

Factor	Event	Impact	Comment
Near-term earnings outlook	4Q22F earnings momentum	+YoY and -QoQ	We expect 4Q22 core earnings to grow YoY but drop QoQ on seasonal year-end expense adjustment and lower revenue from COVID-19 services.
Factors to be aware of in 2022-23	Lift of travel restrictions	Positive impact	The removal of travel restrictions is encouraging more fly-in and medical tourism patients to come to Thailand. BDMS expects revenue from international patient services to reach pre-COVID-19 level in 4Q22.

Sensitivity analysis

Factor	Earnings impact	TP impact
1ppt change in hospital revenue	2-3%	Bt0.5/share (2%)

ESG Disclosure Score

Bloomberg ESG Score	57.69 (2021)
Rank in Sector	1/23

	CG Rating 0-5	DJSI	SETTHSI	THSI
BDMS	5	Yes	Yes	Yes

Source: Thai Institute of Directors (IOD), SET

Environmental Issue (E)

- BDMS subsidiaries participated in Care the Bear project hosted by The Stock Exchange of Thailand (SET) in 2021 to mitigate climate change from business activities.
- In 2021, BDMS delivered 802,007.04 kgCO₂eq greenhouse gas reduction, equivalent to the annual greenhouse gas absorption by 89,119 trees. This was improved from 2020's 5,039.30 kgCO₂eq greenhouse gas reduction, equivalent to the annual greenhouse gas absorption by 560 trees.
- 76% of network hospital medical laboratories were certified ISO 15190:2003 covering hazardous and non-hazardous waste and chemical management.

Social Issue (S)

- Bt65.63mn social contribution value through CSR projects.
- BDMS has projects to improve physician engagement and continuously surveys physician engagement in several aspects to ensure physician willingness to perform duties with dedication and engagement. Its physician engagement level is 83.76% against its target of 83%.
- BDMS does an annual engagement survey of all staff. This shows 82% of employee engagement in BDMS (excluding physicians), above target of 75%.

Governance Issue (G)

- There are 18 directors in total, consisting of 8 executive directors (44.44% of all directors), 2 non-executive directors (11.11% of all directors) and 8 independent directors (44.44% of all directors) that is not less one-third (1/3) of the Board of Directors.
- The chairman is an independent director.
- Major shareholders control ~20% of total issued and paid-up shares.

ESG Disclosure Score

	2020	2021
ESG Disclosure Score	57.69	57.69
Environment	52.31	52.31
Emissions Reduction Initiatives	No	No
Climate Change Policy	Yes	Yes
GHG Scope 1	35.41	8.67
GHG Scope 2 Location-Based	94.50	95.94
Energy Efficiency Policy	Yes	Yes
Total Energy Consumption	146.91	193.80
Waste Reduction Policy	Yes	Yes
Total Waste	5.43	9.05
Water Policy	Yes	Yes
Total Water Withdrawal	1,729.44	2,406.97
Social	37.06	37.06
Human Rights Policy	Yes	Yes
Consumer Data Protection Policy	Yes	Yes
Pct Women in Workforce	81.60	82.63
Lost Time Incident Rate - Employees	0.01	0.00
Number of Employees - CSR	36,254	36,344
Total Hours Spent by Firm - Employee Training	476,816	437,209
Governance	83.59	83.59
Size of the Board	16	18
Board Meeting Attendance Pct	98	97
Number of Independent Directors	7	8
% Independent directors to total board members	44	44
Board Duration (Years)	3	3

Source: Bloomberg Finance L.P.

Disclaimer

Bloomberg ESG Disclosure Scores rate companies on their level of disclosure of ESG data. Bloomberg offers four disclosure scores, for overall ESG, as well as Environmental, Social, and Governance such as energy consumption, board composition, and workforce accidents.

Company ESG reporting has evolved since our ESG Disclosure Score was originally created in 2010. In order to reflect the evolution in corporate reporting, in early 2022 Bloomberg updated its ESG disclosure scores methodology. The methodology changes were implemented for all years of data for all companies in the ESG Coverage universe.

To review the fully transparent methodology, calculate disclosure scores for any company, and compare a company's scores vs its peers, see ESG Disclosure Score Model in Bloomberg.

Financial statement

Profit and Loss Statement

FY December 31	Unit	2017	2018	2019	2020	2021	2022F	2023F	2024F
Total revenue	(Btmn)	69,123	75,331	79,630	65,166	71,541	87,165	92,867	99,508
Cost of goods sold	(Btmn)	47,975	51,546	54,277	46,371	49,462	58,916	63,313	67,328
Gross profit	(Btmn)	21,148	23,784	25,354	18,795	22,079	28,248	29,554	32,180
SG&A	(Btmn)	14,488	15,998	17,447	14,161	15,029	16,860	16,512	17,524
Other income	(Btmn)	4,402	4,803	11,882	5,187	4,050	5,056	5,386	5,473
Interest expense	(Btmn)	1,535	1,165	929	871	728	665	638	409
Pre-tax profit	(Btmn)	9,526	11,424	18,860	8,950	10,373	15,779	17,791	19,721
Corporate tax	(Btmn)	2,564	2,740	3,873	2,751	2,103	2,998	3,380	3,944
Equity a/c profits	(Btmn)	1,417	1,690	1,022	273	21	40	44	46
Minority interests	(Btmn)	(359)	(456)	(492)	(435)	(554)	(601)	(721)	(757)
Core profit	(Btmn)	8,021	9,918	9,560	6,037	7,736	12,220	13,733	15,066
Extra-ordinary items	(Btmn)	2,195	(727)	5,957	1,177	200	0	0	0
Net Profit	(Btmn)	10,216	9,191	15,517	7,214	7,936	12,220	13,733	15,066
EBITDA	(Btmn)	15,544	17,249	18,032	14,982	17,622	22,782	25,072	26,988
Core EPS (Bt)	(Btmn)	0.52	0.64	0.61	0.38	0.49	0.77	0.86	0.95
Net EPS (Bt)	(Bt)	0.66	0.59	0.99	0.46	0.50	0.77	0.86	0.95
DPS (Bt)	(Bt)	0.36	0.32	0.55	0.55	0.45	0.50	0.50	0.50

Balance Sheet

FY December 31	Unit	2017	2018	2019	2020	2021	2022F	2023F	2024F
Total current assets	(Btmn)	14,359	15,198	16,325	30,013	24,401	17,932	24,480	28,732
Total fixed assets	(Btmn)	71,559	74,496	78,440	81,313	79,689	80,706	79,487	78,385
Total assets	(Btmn)	122,627	133,499	133,662	136,050	128,454	122,529	127,387	130,066
Total loans	(Btmn)	30,456	39,849	24,316	20,701	15,672	6,496	4,996	0
Total current liabilities	(Btmn)	13,417	28,499	19,263	11,220	15,862	11,546	11,995	12,426
Total long-term liabilities	(Btmn)	37,694	29,790	24,099	20,594	15,596	6,496	4,996	0
Total liabilities	(Btmn)	56,756	60,061	46,480	44,588	40,689	30,372	29,322	24,756
Paid-up capital	(Btmn)	1,549	1,567	1,589	1,589	1,589	1,589	1,589	1,589
Total equity	(Btmn)	65,871	73,438	87,182	91,463	87,765	92,157	98,065	105,310
BVPS (Bt)	(Bt)	4.07	4.50	5.33	5.59	5.28	5.54	5.91	6.36

Cash Flow Statement

FY December 31	Unit	2017	2018	2019	2020	2021	2022F	2023F	2024F
Core Profit	(Btmn)	8,021	9,918	9,560	6,037	7,736	12,220	13,733	15,066
Depreciation and amortization	(Btmn)	5,168	5,386	5,752	6,413	6,321	6,338	6,643	6,859
Operating cash flow	(Btmn)	10,933	14,804	14,546	11,681	14,561	17,148	19,700	21,133
Investing cash flow	(Btmn)	(11,870)	(13,351)	2,818	12,385	(4,763)	(6,573)	(4,643)	(4,975)
Financing cash flow	(Btmn)	1,811	(1,511)	(17,701)	(9,096)	(18,531)	(17,367)	(9,325)	(12,817)
Net cash flow	(Btmn)	874	(58)	(337)	14,970	(8,733)	(6,792)	5,732	3,340

Key Financial Ratios

FY December 31	Unit	2017	2018	2019	2020	2021	2022F	2023F	2024F
Gross margin	(%)	30.6	31.6	31.8	28.8	30.9	32.4	31.8	32.3
Operating margin	(%)	9.6	10.3	9.9	7.1	9.9	13.1	14.0	14.7
EBITDA margin	(%)	21.3	21.7	21.5	21.7	23.3	24.7	25.5	25.7
EBIT margin	(%)	19.2	15.7	24.9	16.9	15.8	18.9	19.8	20.2
Net profit margin	(%)	14.8	12.2	19.5	11.1	11.1	14.0	14.8	15.1
ROE	(%)	12.9	14.2	11.9	6.8	8.6	13.6	14.4	14.8
ROA	(%)	7.0	7.7	7.2	4.5	5.8	9.7	11.0	11.7
Net D/E	(x)	0.5	0.5	0.3	(0.0)	0.1	0.0	(0.1)	(0.1)
Interest coverage	(x)	10.1	14.8	19.4	17.2	24.2	34.3	39.3	66.1
Debt service coverage	(x)	5.1	1.1	2.9	15.3	4.5	34.3	39.3	66.1
Payout Ratio	(%)	55	54	55.8	120.0	90.1	65.0	57.9	52.7

Main Assumptions

FY December 31	Unit	2017	2018	2019	2020	2021	2022F	2023F	2024F
Revenue by nationality									
International	(%)	30.0	30.0	30.0	21.0	18.0	22.2	29.3	30.9
Thai	(%)	70.0	70.0	70.0	79.0	82.0	77.8	70.7	69.1

Financial statement

Profit and Loss Statement

FY December 31	Unit	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22
Total revenue	(Btmn)	17,134	15,311	16,443	18,873	20,914	22,165	20,976	22,825
Cost of goods sold	(Btmn)	12,315	11,051	11,762	13,125	13,525	14,451	14,147	14,979
Gross profit	(Btmn)	4,819	4,261	4,681	5,749	7,389	7,714	6,829	7,846
SG&A	(Btmn)	3,985	3,284	3,539	3,514	4,691	4,025	4,200	4,496
Other income	(Btmn)	3,394	983	992	1,297	978	1,007	1,030	1,179
Interest expense	(Btmn)	210	195	188	172	173	158	151	154
Pre-tax profit	(Btmn)	4,019	1,765	1,946	3,359	3,503	4,538	3,508	4,374
Corporate tax	(Btmn)	2,702	330	383	845	746	903	695	824
Equity a/c profits	(Btmn)	26	3	5	3	10	9	7	16
Minority interests	(Btmn)	(120)	(99)	(116)	(208)	(131)	(201)	(155)	(181)
Core profit	(Btmn)	1,224	1,339	1,452	2,309	2,636	3,443	2,664	3,386
Extra-ordinary items	(Btmn)	1,164	0	0	200	0	0	0	0
Net Profit	(Btmn)	2,388	1,339	1,452	2,509	2,636	3,443	2,664	3,386
EBITDA	(Btmn)	5,839	3,541	3,718	5,132	5,232	6,186	5,144	6,018
Core EPS (Bt)	(Btmn)	0.08	0.08	0.09	0.15	0.17	0.22	0.17	0.21
Net EPS (Bt)	(Bt)	0.15	0.08	0.09	0.16	0.17	0.22	0.17	0.21

Balance Sheet

FY December 31	Unit	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22
Total current assets	(Btmn)	30,013	31,668	19,341	24,337	24,401	27,176	30,255	27,074
Total fixed assets	(Btmn)	81,313	80,839	80,342	79,996	79,689	79,506	79,190	79,490
Total assets	(Btmn)	136,050	137,009	124,183	128,842	128,454	131,098	133,780	133,875
Total loans	(Btmn)	20,701	20,677	15,670	15,595	15,672	13,096	16,097	15,997
Total current liabilities	(Btmn)	11,220	13,369	12,619	19,132	15,862	18,887	22,801	22,966
Total long-term liabilities	(Btmn)	20,594	20,594	15,595	15,595	15,596	13,096	13,097	13,497
Total liabilities	(Btmn)	44,588	44,168	38,525	44,328	40,689	39,802	42,817	43,586
Paid-up capital	(Btmn)	1,589	1,589	1,589	1,589	1,589	1,589	1,589	1,589
Total equity	(Btmn)	91,463	92,841	85,658	84,513	87,765	91,296	90,962	90,289
BVPS (Bt)	(Bt)	5.53	5.62	5.16	5.08	5.28	5.49	5.47	5.41

Cash Flow Statement

FY December 31	Unit	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22
Core Profit	(Btmn)	1,224	1,339	1,452	2,309	2,636	3,443	2,664	3,386
Depreciation and amortization	(Btmn)	1,610	1,581	1,584	1,600	1,556	1,490	1,486	1,490
Operating cash flow	(Btmn)	3,943	4,008	2,118	3,238	5,198	5,147	4,382	3,660
Investing cash flow	(Btmn)	16,653	(1,102)	(593)	(1,712)	(1,355)	(2,145)	(1,256)	(1,966)
Financing cash flow	(Btmn)	(5,009)	(206)	(14,063)	(157)	(4,105)	(2,636)	(547)	(4,980)
Net cash flow	(Btmn)	15,587	2,699	(12,538)	1,368	(262)	366	2,579	(3,285)


Key Financial Ratios

FY December 31	Unit	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22
Gross margin	(%)	28.1	27.8	28.5	30.5	35.3	34.8	32.6	34.4
Operating margin	(%)	4.9	6.4	6.9	11.8	12.9	16.6	12.5	14.7
EBITDA margin	(%)	18.9	21.7	21.3	25.4	23.9	26.7	23.4	25.1
EBIT margin	(%)	24.7	12.8	13.0	18.7	17.6	21.2	17.4	19.8
Net profit margin	(%)	13.9	8.7	8.8	13.3	12.6	15.5	12.7	14.8
ROE	(%)	6.8	6.1	6.6	8.0	8.6	15.0	13.8	14.5
ROA	(%)	4.5	3.8	4.3	5.2	5.8	10.3	9.5	9.6
Net D/E	(x)	(0.0)	(0.0)	0.1	0.1	0.1	0.0	0.1	0.1
Interest coverage	(x)	27.8	18.2	19.8	29.7	30.3	39.1	34.0	39.1
Debt service coverage	(x)	24.7	4.2	4.5	5.4	5.4	4.7	2.2	3.0

Main Assumptions


FY December 31	Unit	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22
Revenue by nationality									
International	(%)	17.0	19.0	18.0	17.0	18.0	22.0	24.0	24.0
Thai	(%)	83.0	81.0	82.0	83.0	82.0	78.0	76.0	76.0

Figure 1: BDMS hospital revenue




Source: Company data and InnovestX Research

Figure 2: BDMS quarterly earnings




Source: Company data and InnovestX Research

Figure 3: BDMS' revenue from non-COVID-19 services is improving




Source: Company data and InnovestX Research




Source: Company data and InnovestX Research

Figure 4: A strong increase of appointments of international patients



Source: Company data

Figure 5: BDMS earnings forecast



Source: Company data and InnovestX Research

Figure 6: Valuation summary (price as of Nov 28, 2022)

	Rating	Price (Bt/Sh)	Target (Bt/Sh)	ETR (%)	P/E (x)			EPS growth (%)			P/BV (x)			ROE (%)			Div. Yield (%)			EV/EBITDA (x)		
					21A	22F	23F	21A	22F	23F	21A	22F	23F	21A	22F	23F	21A	22F	23F	21A	22F	23F
BCH	Neutral	20.30	24.0	21.4	7.4	12.4	28.0	442.3	(40.5)	(55.6)	3.9	3.5	3.3	62	27	11	3.9	3.1	1.8	5.1	9.7	14.4
BDMS	Outperform	29.00	34.0	19.0	59.6	37.7	33.6	26.9	58.0	12.4	5.5	5.2	4.9	9	14	14	1.6	1.7	1.7	26.5	20.3	18.1
BH	Neutral	217.00	200.0	(6.4)	140.6	35.1	32.4	2.2	300.3	8.6	10.0	8.8	7.7	7	26	25	1.5	1.5	1.5	111.2	22.9	20.8
CHG	Neutral	3.60	4.0	16.1	9.4	14.1	29.0	379.6	(33.2)	(51.3)	5.2	4.8	5.2	70	34	17	5.6	5.0	2.4	6.6	9.2	16.8
RJH	Neutral	30.50	35.0	24.3	9.0	8.4	22.6	145.3	8.1	(62.9)	4.7	4.2	4.0	58	53	18	8.9	9.6	3.5	6.8	6.3	13.5
Average					45.2	21.5	29.1	199.3	58.5	(29.8)	6.2	5.6	5.3	37	25	17	3.1	2.8	1.9	37.4	15.5	17.5

Source: InnovestX Research

Disclaimer

The information in this report has been obtained from sources believed to be reliable. However, its accuracy or completeness is not guaranteed. Any opinions expressed herein reflect our judgment at this date and are subject to change without notice. This report is for information only. It is not to be construed as an offer, or solicitation of an offer to sell or buy any securities. We accept no liability for any loss arising from the use of this document. We or our associates may have an interest in the companies mentioned therein.

InnovestX Securities Company Limited ("INVX") is a wholly-owned subsidiary of The Siam Commercial Bank Public Company Limited ("SCB"). Any information related to SCB is for sector comparison purposes.

This document is prepared by InnovestX Securities Company Limited ("INVX") which is wholly-owned by The Siam Commercial Bank Public Company Limited ("SCB"). SCB acts as financial advisor of the SCG Chemicals Public Company Limited (SCGC). Any opinions, news, research, analyses, prices, statements, forecasts, projections and/or other information contained in this document (the "Information") is provided as general information purposes only and shall not be construed as individualized recommendation of an offer to buy or sell or the solicitation of an offer to buy or sell any securities. INVX and/or its directors, officers and employees shall not be liable for any direct, indirect, incidental, special or consequential loss or damage, resulting from the use of or reliance on the Information, including without limitation to, damages for loss of profits. The investors shall use the Information in association with other information and opinion, including their own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and INVX cannot guarantee the accuracy, completeness and/or correctness of the Information.

This document is prepared by InnovestX Securities Company Limited ("INVX") which is wholly-owned by The Siam Commercial Bank Public Company Limited ("SCB"). SCB may be appointed to act as financial advisor in relation to transactions to be carried out by Thai Oil Company Limited. Any opinions, news, research, analyses, prices, statements, forecasts, projections and/or other information contained in this document (the "Information") is provided as general information purposes only and shall not be construed as individualized recommendation of an offer to buy or sell or the solicitation of an offer to buy or sell any securities. INVX and/or its directors, officers and employees shall not be liable for any direct, indirect, incidental, special or consequential loss or damage, resulting from the use of or reliance on the Information, including without limitation to, damages for loss of profits. The investors shall use the Information in association with other information and opinion, including their own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and INVX cannot guarantee the accuracy, completeness and/or correctness of the Information.

This document is prepared by InnovestX Securities Company Limited ("INVX") which is wholly-owned by The Siam Commercial Bank Public Company Limited ("SCB"). SCB has acted as Financial Advisor, Lead Arranger of Global Power Synergy Public Company Limited. Any opinions, news, research, analyses, prices, statements, forecasts, projections and/or other information contained in this document (the "Information") is provided as general information purposes only, and shall not be construed as individualized recommendation of an offer to buy or sell or the solicitation of an offer to buy or sell any securities. INVX and/or its directors, officers and employees shall not be liable for any direct, indirect, incidental, special or consequential loss or damage, resulting from the use of or reliance on the Information, including without limitation to, damages for loss of profits. The investors shall use the Information in association with other information and opinion, including their own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and INVX cannot guarantee the accuracy, completeness and/or correctness of the Information.

This document is prepared by InnovestX Securities Company Limited ("INVX") which is wholly-owned by The Siam Commercial Bank Public Company Limited ("SCB"). SCB Asset Management Company Limited ("SCBAM") which is wholly-owned by The Siam Commercial Bank Public Company Limited ("SCB"). SCB has acted as Financial Advisor of Digital Telecommunications Infrastructure Fund. SCBAM has acted as Fund Manager of Digital Telecommunications Infrastructure Fund. Any opinions, news, research, analyses, prices, statements, forecasts, projections and/or other information contained in this document (the "Information") is provided as general information purposes only, and shall not be construed as individualized recommendation of an offer to buy or sell or the solicitation of an offer to buy or sell any securities. INVX and/or its directors, officers and employees shall not be liable for any direct, indirect, incidental, special or consequential loss or damage, resulting from the use of or reliance on the Information, including without limitation to, damages for loss of profits. The investors shall use the Information in association with other information and opinion, including their own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and INVX cannot guarantee the accuracy, completeness and/or correctness of the Information.

INVX reserves the right to modify the Information from time to time without notice and in its sole discretion. This document is delivered to intended recipient(s) only and is not permitted to reproduce, retransmit, disseminate, sell, distribute, republish, circulate or commercially exploit the Information in any manner without the prior written consent of INVX.

Futures and Options trading carry a high level of risk with the potential for substantial losses, and are not suitable for all persons. Before deciding to trade Futures and Options, you should carefully consider your financial position, investment objectives, level of experience, and risk appetite if Futures and Options trading are appropriate. The possibility exists that you could sustain a loss of some or all of your initial investment. You should be aware of all the risks associated with Futures and Options trading, and you are advised to rely on your own judgment while making investment decision and/or should seek advice from professional investment advisor if you have any doubts.

This document is delivered to intended recipient(s) only and is not permitted to reproduce, retransmit, disseminate, sell, distribute, republish, circulate or commercially exploit the Information in any manner without the prior written consent of INVX.

© Copyright 2022 InnovestX Securities Co., Ltd. All right reserved.

CG Rating 2022 Companies with CG Rating

Companies with Excellent CG Scoring

AAV, ADVANC, AF, AH, AIRA, AJ, AKP, AKR, ALLA, ALT, AMA, AMARIN, AMATA, AMATAV, ANAN, AOT, AP, APURE, ARIP, ASP, ASW, AUCTION, AWC, AYUD, BAFS, BAM, BANPU, BAY, BBIK, BBL, BCP, BCPG, BDMS, BEM, BEYOND, BGC, BGRIM, BIZ, BKI, BOL, BPP, BRR, BTS, BTW, BWG, CENTEL, CFRESH, CGH, CHEWA, CHO, CIMBT, CK, CKP, CM, CNT, COLOR, COM7, COMAN, COTTO, CPALL, CPF, CPI, CPN, CRC, CSS, DDD, DELTA, DEMCO, DOHOME, DRT, DTAC, DUSIT, EA, EASTW, ECF, ECL, EE, EGCO, EPG, ETC, ETE, FN, FNS, FPI, FPT, FSMART, FVC, GC, GEL, GFPT, GGC, GLAND, GLOBAL, GPI, GPSC, GRAMMY, GULF, GUNKUL, HANA, HARN, HENG, HMPRO, ICC, ICHI, III, ILINK, ILM, IND, INTUCH, IP, IRC, IRPC, ITCL, IVL, JTS, JWD, K, KBANK, KCE, KEX, KGI, KKP, KSL, KTB, KTC, LALIN, LANNA, LHFG, LIT, LOXLEY, LPN, LRH, LST, MACO, MAJOR, MAKRO, MALEE, MBK, MC, MCOT, METCO, MFEC, MINT, MONO, MOONG, MSC, MST, MTC, MVP, NCL, NEP, NER, NKI, NOBLE, NSI, NVD, NYT, OISHI, OR, ORI, OSP, OTO, PAP, PCSGH, PDG, PDJ, PG, PHOL, PLANB, PLANET, PLAT, PORT, PPS, PR9, PREB, PRG, PRM, PSH, PSL, PTG, PTT, PTTEP, PTTGC, PYLON, Q-CON, QH, QTC, RATCH, RBF, RS, S, S&J, SAAM, SABINA, SAMART, SAMTEL, SAT, SC, SCB, SCC, SCCC, SCG, SCGP, SCM, SCN, SDC, SEAFSCO, SEAOIL, SE-ED, SELIC, SENA, SENAJ, SGF, SHR, SICT, SIRI, SIS, SITHAI, SMPK, SNC, SONIC, SORKON, SPALI, SPI, SPRC, SPVI, SSC, SSSC, SST, STA, STEC, STGT, STI, SUN, SUSCO, SUTHA, SVI, SYMC, SYNTEC, TACC, TASCO, TAPAC, TEAMG, TFMAMA, THANA, THANI, THCOM, THG, THIP, THRE, THREL, TIPCO, TISCO, TK, TKN, TKS, TKT, TMILL, TMT, TNDT, TNITY, TOA, TOP, TPBI, TQM, TRC, TRUE, TSC, TSR, TSTE, TSTH, TTA, TTB, TTCL, TTW, TU, TVDH, TVI, TVO, TWPC, U, UAC, UBIS, UPOIC, UV, VCOM, VGI, VIH, WACOAL, WAVE, WHA, WHAUP, WICE, WINNER, XPG, ZEN

Companies with Very Good CG Scoring

2S, 7UP, ABICO, ABM, ACE, ACG, ADB, ADD, AEONTS, AGE, AHC, AIE, AIT, ALUCON, AMANAH, AMR, APCO, APCS, AQUA, ARIN, ARROW, AS, ASAP, ASEFA, ASIA, ASIAN, ASIMAR, ASK, ASN, ATP30, B, BA, BC, BCH, BE8, BEC, SCAP, BH, BIG, BJC, BJCHI, BLA, BR, BRI, BROOK, BSM, BYD, CBG, CEN, CHARAN, CHAYO, CHG, CHOTI, CHOW, CI, CIG, CITY, CIVIL, CMC, CPL, CPW, CRANE, CRD, CSC, CSP, CV, CWT, DCC, DHOUSE, DITTO, DMT, DOD, DPAINT, DV8, EASON, EFORL, ERW, ESSO, ESTAR, FE, FLOYD, FORTH, FSS, FTE, GBX, GCAP, GENCO, GJS, GTB, GYT, HEMP, HPT, HTC, HUMAN, HYDRO, ICN, IFS, IIG, IMH, INET, INGRS, INSET, INSURE, IRCP, IT, ITD, J, JAS, JCK, JCKH, JMT, JR, KBS, KCAR, KIAT, KISS, KK, KOOL, KTIS, KUMWEL, KUN, KWC, KWM, L&E, LDC, LEO, LH, LHK, M, MATCH, MBAX, MEGA, META, MFC, MGT, MICRO, MILL, MITSIB, MK, MODERN, MTI, NBC, NCAP, NCH, NDR, NETBAY, NEX, NINE, NATION, NNCL, NOVA, NPK, NRF, NTV, NUSA, NWR, OCC, OGC, ONEE, PACO, PATO, PB, PICO, PIMO, PIN, PJW, PL, PLE, PM, PMTA, PPP, PPPM, PRAPAT, PRECHA, PRIME, PRIN, PRINC, PROEN, PROS, PROUD, PSG, PSTC, PT, PTC, QLT, RCL, RICHY, RJH, ROJNA, RPC, RT, RWI, S11, SA, SABUY, SAK, SALEE, SAMCO, SANKO, SAPPE, SAWAD, SCI, SCP, SE, SECURE, SFLEX, SFP, SFT, SGP, SIAM, SINGER, SKE, SKN, SKR, SKY, SLP, SMART, SMD, SMIT, SMT, SNNP, SNP, SO, SPA, SPD, SPCG, SR, SRICHA, SSF, SSP, STANLY, STARK, STC, STPI, SUC, SVOA, SVT, SWC, SYNEX, TAE, TAKUNI, TCC, TCMC, TFG, TFI, TFM, TGH, TIDLO, TIGER, TIPH, TITLE, TM, TMC, TMD, TMI, TNL, TNP, TNR, TOG, TPA, TPAC, TPCS, TPIPL, TPIPP, TPLAS, TPS, TQR, TRITN, TRT, TRU, TRV, TSE, TVT, TWP, UBE, UEC, UKEM, UMI, UOBKH, UP, UPF, UTP, VIBHA, VL, VPO, VRANDA, WGE, WIKI, WIN, WINMED, WORK, WP, XO, YUASA, ZIGA

Companies with Good CG Scoring

A, A5, AI, ALL, ALPHAX, AMC, APP, AQ, AU, B52, BEAUTY, BGT, BLAND, BM, BROCK, BSBM, BTNC, CAZ, CCP, CGD, CMAN, CMO, CMR, CPANEL, CPT, CSR, CTW, D, DCON, EKH, EMC, EP, EVER, F&D, FMT, GIFT, GLOCON, GLORY, GREEN, GSC, HL, HTECH, IHL, INOX, JAK, JMART, JSP, JUBILE, KASET, KCM, KWI, KYE, LEE, LPH, MATI, M-CHAI, MCS, MDX, MENA, MJD, MORE, MPIC, MUD, NC, NEWS, NFC, NSL, NV, PAF, PEACE, PF, PK, PPM, PRAKIT, PTL, RAM, ROCK, RP, RPH, RSP, SIMAT, SISB, SK, SOLAR, SPACK, SPG, SQ, STARK, STECH, SUPER, SVH, PTECH, TC, TCCC, TCJ, TEAM, THE, THMUI, TKC, TNH, TNPC, TOPP, TPCH, TPOLY, TRUBB, TTI, TYCN, UMS, UNIQU, UREA, VARIO, W, WFX, WPH, YGG

Corporate Governance Report

The material contained in this publication is for general information only and is not intended as advice on any of the matters discussed herein. Readers and others should perform their own independent analysis as to the accuracy or completeness or legality of such information. The Thai Institute of Directors, its officers, the authors and editor make no representation or warranty as to the accuracy, completeness or legality of any of the information contained herein. By accepting this document, each recipient agrees that the Thai Institute of Directors Association, its officers, the authors and editor shall not have any liability for any information contained in, or for any omission from, this publication.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. InnovestX Securities Company Limited does not conform nor certify the accuracy of such survey result.

To recognize well performers, the list of companies attaining "Good", "Very Good" and "Excellent" levels of recognition (Not including listed companies qualified in the "no announcement of the results" clause from 1 January 2021 to 27 October 2022) is publicized.

* บริษัทหรือกรรมการหรือผู้บริหารของบริษัทที่มีส่วนดำเนินการกำกับดูแลกิจการ เช่น การกระทำเกี่ยวกับหลักทรัพย์ การทุจริต คอรัปชั่น เป็นต้น ซึ่งการใช้ข้อมูล CGR ควรระมัดระวังข้อมูลที่เกี่ยวข้องกับกลุ่มตัวอย่าง

Anti-corruption Progress Indicator

Certified (ได้เริ่มรับรอง)

2S, 7UP, ADVANC, AF, AI, AIE, AIRA, AJ, AKP, AMA, AMANAH, AMATA, AMATAV, AP, APCS, AS, ASIAN, ASK, ASP, AWC, AYUD, B, BAFS, BAM, BANPU, BAY, BBL, BCH, BCP, BCPG, BE8, BEC, BEYOND, BGC, BGRIM, BKI, BLA, BPP, BROOK, BRR, BSBM, BTS, BWG, CEN, CENTEL, CFRESH, CGH, CHEWA, CHOTI, CHOW, CIG, CIMBT, CM, CMC, COM7, COTTO, CPALL, CPF, CPI, CPL, CPN, CRC, CSC, DCC, DELTA, DEMCO, DIMET, DRT, DTAC, DUSIT, EA, EASTW, EGCO, EP, EPG, ERW, ESTAR, ETE, FE, FNS, FPI, FPT, FSMART, FSS, FTE, GBX, GC, GCAP, GEL, GFPT, GGC, GJS, GPI, GPSC, GSTEEL, GULF, GUNKUL, HANA, HARN, HEMP, HENG, HMPRO, HTC, ICC, ICHI, IFS, III, ILINK, INET, INSURE, INTUCH, IRC, IRPC, ITCL, IVL, JKN, JR, K, KASET, KBANK, KBS, KCAR, KCE, KGI, KKP, KSL, KTB, KTC, KWI, L&E, LANNA, LH, LHFG, LHK, LPN, LRH, M, MAJOR, MAKRO, MALEE, MATCH, MBAX, MBK, MC, MCOT, META, MFC, MFEC, MILL, MINT, MONO, MOONG, MSC, MST, MTC, MTI, NBC, NEP, NINE, NKI, NOBLE, NOK, NSI, NWR, OCC, OGC, ORI, PAP, PATO, PB, PCSGH, PDG, PDJ, PG, PHOL, PK, PL, PLANB, PLANET, PLAT, PM, PPP, PPPM, PPS, PR9, PREB, PRG, PRINC, PRM, PROS, PSH, PSL, PSTC, PT, PTG, PTT, PTTEP, PTTGC, PYLON, Q-CON, QH, QLT, QTC, RATCH, RML, RWI, S&J, SAAM, SABINA, SAPPE, SAT, SC, SCB, SCC, SCCC, SCG, SCGP, SCM, SCN, SEAOIL, SE-ED, SELIC, SENA, SGP, SINGER, SIRI, SITHAI, SKR, SMIT, SMK, SMPK, SNC, SNP, SORKON, SPACK, SPALI, SPC, SPI, SPRC, SRICHA, SSF, SSP, SSSC, SST, STA, STGT, STOWER, SUSCO, SVI, SYMC, SYNTEC, TAE, TAKUNI, TASCO, TAPAC, TCMC, TFG, TFI, TFMAMA, TGH, THANI, THCOM, THIP, THRE, THREL, TIDLO, TIPCO, TISCO, TKS, TKT, TMILL, TMT, TNITY, TNL, TNP, TNR, TOG, TOP, TOPP, TPA, TPCS, TPP, TRU, TRUE, TSC, TSTE, TSTH, TTA, TTB, TTCL, TU, TVDH, TVI, TVO, TWPC, U, UBE, UBIS, UEC, UKEM, UOBKH, UPF, UV, VGI, VIH, WACOAL, WHA, WHAUP, WICE, WIKI, XO, YUASA, ZEN, ZIGA

Declared (ได้ประกาศเจตนา)

AH, ALT, APCO, ASW, B52, CHG, CI, CPR, CPW, DDD, DHOUSE, DOHOME, ECF, EKH, ETC, EVER, FLOYD, GLOBAL, ILM, INOX, J, JMART, JMT, JTS, KEX, KUMWEL, LDC, MEGA, NCAP, NOVA, NRF, NUSA, OR, PIMO, PLE, RS, SAK, SIS, SSS, STECH, SUPER, SVT, TKN, TMD, TMI, TQM, TRT, TSI, VARIO, VCOM, VIBHA, W, WIN

N/A

24CS, 3K-BAT, A, A5, AAI, AAV, ABICO, ABM, ACAP, ACC, ACE, ACG, ADB, ADD, AEONTS, AFC, AGE, AHC, AIT, AJA, AKR, ALL, ALLA, ALPHAX, ALUCON, AMARC, AMARIN, AMR, AMR, ANAN, AOT, APEG, APP, APURE, AQ, AQUA, ARIN, ARIP, ARROW, ASAP, ASEFA, ASIA, ASIMAR, ASN, ATP30, AU, AUCTION, AURA, BA, BBGI, BBIK, BC, BCT, BDMS, BEAUTY, BEM, BGT, BH, BIG, BIOTECH, BIS, BIZ, BJC, BJCHI, BKD, BLAND, BLESS, BLISS, BM, BOL, BR, BRI, BROCK, BSM, BTG, BTNC, BTW, BUI, BYD, CAZ, CBG, CCET, CCP, CEYE, CGD, CH, CHARAN, CHAYO, CHIC, CHO, CITY, CIVIL, CK, CKP, CMAN, CMO, CMR, CNT, COLOR, COMAN, CPANEL, CPH, CPT, CRANE, CRD, CSP, CSR, CSS, CTW, CV, CWT, D, DCON, DITTO, DMT, DOD, DPAINT, DTCI, DV8, EASON, ECL, EE, EFORL, EMC, ESSO, F&D, FANCY, FMT, FN, FORTH, FTI, FVC, GENCO, GIFT, GL, GLAND, GLOCON, GLORY, GRAMMY, GRAND, GREEN, GSC, GTB, GYT, HFT, HL, HPT, HTECH, HUMAN, HYDRO, ICN, IFEC, IHL, IIG, IMH, IND, INGRS, INSET, IP, IRCP, IT, ITC, ITD, ITNS, JAK, JAS, JCK, JCKH, JCT, JDF, JSP, JUBILE, JWD, KAMART, KC, KCC, KCM, KDH, KIAT, KISS, KJL, KK, KKC, KLINIQ, KOOL, KTIS, KUN, KWC, KWM, KYE, LALIN, LEE, LEO, LIT, LOXLEY, LPH, LST, MACO, MANRIN, MATI, MAX, M-CHAI, MCS, MDX, MENA, METCO, MGT, MICRO, MIDA, MITSIB, MJD, MK, ML, MODERN, MORE, MPIC, MUD, MVP, NATION, NC, NCH, NCL, NDR, NER, NETBAY, NEW, NEWS, NEX, NFC, NNCL, NPK, NSL, NTV, NV, NVD, NYT, OHTL, OISHI, ONEE, OSP, OTO, PACE, PACO, PAF, PCC, PEACE, PERM, PF, PICO, PIN, PJW, PLUS, PMTA, POLAR, POLY, POMPU, PORT, POST, PPM, PRAKIT, PRAPAT, PRECHA, PRI, PRIME, PRIN, PRO, PROEN, PROUD, PSG, PTC, PTECH, PTL, RAM, RBF, RCL, RICHY, RJH, ROCK, ROH, ROJNA, RP, RPC, RPH, RSP, RT, S, S11, SA, SABUY, SAFARI, SALEE, SAM, SAMART, SAMCO, SAMTEL, SANKO, SAUCE, SAWAD, SAWANG, SCAP, SCI, SCP, SDC, SE, SEAFSCO, SECURE, SENAJ, SFLEX, SFP, SFT, SGC, SGF, SHANG, SHR, SIAM, SICT, SIMAT, SISB, SK, SKE, SKN, SKY, SLM, SLP, SMART, SMD, SMT, SNNP, SO, SOLAR, SONIC, SPA, SPCG, SPG, SPVI, SQ, SR, SSC, STANLY, STARK, STC, STEC, STHAI, STI, STP, STPI, SUC, SUN, SUTHA, SVH, SVOA, SWC, SYNEX, TACC, TAPAC, TC, TCC, TCCC, TCJ, TCOAT, TEAM, TEAMG, TEGH, TEKA, TFM, TGE, TGPRO, TH, THAI, THANA, THE, THG, THL, THMUI, TIGER, TIPH, TITL, TK, TKC, TLI, TM, TMC, TMW, TNDT, TNH, TNPC, TOA, TPAC, TPBI, TPCH, TPIPL, TPIPP, TPOLY, TPS, TQR, TR, TRC, TRITN, TRUBB, TRV, TSE, TFS, TSI, TTT, TTW, TVT, TWP, TWZ, TYCN, UAC, UMI, UMS, UNIQU, UP, UPA, UPOIC, UREA, UTP, UVAN, VL, VNG, VPO, VRANDA, WAVE, WFX, WGE, WINMED, WINNER, WORK, WORLD, WP, WPH, XPG, YGG, YONG

Explanations

Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of July 7, 2022) are categorised into: companies that have declared their intention to join CAC, and companies certified by CAC.